S.R. Burzynski M.D., Ph.D. Announces Approval of Facility to Manufacture Antineoplastons for Poland.

HOUSTON -- The intent of the release dated July 22, 2004 by S.R. Burzynski, M.D., Ph.D. was to announce the approval of its pharmaceutical manufacturing facility in Stafford, Texas, for initial production of cancer medications to be distributed in Poland and, eventually, in the E.U. The release was not intended to mean that a manufacturing plant would be built in Poland. The decision to construct a plant in Poland will be made in the future, after an evaluation of demand and market conditions.

The corrected release reads:

S.R. BURZYNSKI M.D., PH.D. ANNOUNCES APPROVAL OF FACILITY TO MANUFACTURE ANTINEOPLASTONS FOR POLAND

Lubgen Farma Sp. zo.o., a wholly owned subsidiary of S.R. Burzynski (OTCBB:BZYR), has announced that the Polish government's Chief Pharmaceutical Inspector in Warsaw, Poland, approved the company's manufacturing facility in Stafford, Texas (near Houston) for manufacturing Dr. Burzynski's patented cancer therapy, Antineoplastons, for distribution in Poland.

This marks a significant milestone toward gaining market approval for the experimental targeted gene therapy in Poland and, ultimately, in the European Union. Poland became a member of the European Union on June 1, 2004 and products approved for use in that country will generally be accepted by other E.U. nations.

"This endorsement is another milestone in a line of significant achievements for our company," said Paul Leverett, Managing Director of S.R. Burzynski. "We are committed to fulfilling this critical, unmet medical need for people around the world who are faced with this devastating and deadly disease."

Founded in 1977 by S.R. Burzynski M.D., Ph.D., The Burzynski Clinic has treated more than 8,000 patients, suffering from all types of cancer, with specialized forms of targeted cancer therapy. The Burzynski Clinic is committed to offering the highest standard of healthcare, while providing patients a choice of therapies, a caring environment, control over their lives and an individualized care plan for each patient to achieve optimal results. In cooperation with the Clinic, The Burzynski Research Institute continually screens new compounds for anticancer potential, works to better understand the mechanism of various cancer inhibitors and researches the development of next generation cancer therapies. Together, the staff of 120 doctors, researchers and support personnel at the Burzynski Clinic and Burzynski Research Institute are turning progress into promise for cancer patients.